Publisher, "Spinal cord injury - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Spinal cord injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Spinal cord injury Understanding
Spinal cord injury: Overview
Spinal cord injury is defined as traumatic damage to the spinal cord or nerves at the end of the spinal canal. This affects the conduction of sensory and motor signals across the site of the lesion. Spinal cord injury is a debilitating neurological condition with tremendous socioeconomic impact on affected individuals and the health care system. Spinal cord injury are two types: incomplete and complete injury.Incomplete Lesion: not all the nerves are severed or the nerves are only slightly damaged. Recovery is possible, but never to pre-injury level. Complete lesion: the nerves are severed and there is no motor or sensory function preserved of this point.
"Spinal cord injury - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spinal cord injury pipeline landscape is provided which includes the disease overview and Spinal cord injury treatment guidelines. The assessment part of the report embraces, in depth Spinal cord injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal cord injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spinal cord injury R&D. The therapies under development are focused on novel approaches to treat/improve Spinal cord injury.
Spinal cord injury Emerging Drugs Chapters
This segment of the Spinal cord injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spinal cord injury Emerging Drugs
- KP-100IT: Kringle Pharma
HGF (KP-100IT) protects neurons and promotes the extension of axons, it can be developed as a potential treatment for spinal cord injury. It is currently in Phase III for spinal cord injury. It is being developed by Kringle Pharma.
- ES135: Eusol Biotech
ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. With its effect to promote neurite outgrowth, ES135 can be applied to the medical use of repairing neuron function. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. A multi-center, double blind, randomized, placebo control study as the pivotal Phase 3 clinical trial for spinal cord injury is on-going.
- Elezanumab: AbbVie
Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor thus potentially promoting neuroregeneration. It is currently in phase 2 stage of development.
- Sovateltide: Pharmazz
Sovateltide is an endothelin B (ETB) receptor agonist. Activation of ETB receptors with PMZ-1620 produces neurovascular repair and remodeling or neuroregeneration. It is currently in Phase 2 for acute spinal cord injury.
- FAB117-HC: Histocell
FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2. The HC016 platform is a treatment of acute spinal cord injury in the initial stage of the lesion, based on mesenchymal stem cells derived from adipose tissue (ASC), and improved with Histocell's proprietary technology. Currently in phase 1/2 of development stage for spinal cord injuries.
- NEU-2000: AmKor Pharma
NMDA antagonism and antioxidant action of Nelonemdaz (NEU-2000) would prevent the damages of brain and spinal cord cells induced by Traumatic Brain Injury (TBI) & Traumatic Spinal Cord Injury (TSI). It is currently in Phase I for spinal cord injury. Nelonemdaz is designed as the first multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+-permeable glutamate receptor, and free radicals, two major routes of neuronal death in stroke and traumatic brain/spinal cord injury.
Further product details are provided in the report..
Spinal cord injury: Therapeutic Assessment
This segment of the report provides insights about the different Spinal cord injury drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Spinal cord injury
There are approx. 35+ key companies which are developing the therapies for Spinal cord injury. The companies which have their Spinal cord injury drug candidates in the most advanced stage, i.e. phase III include, Kringle Pharma.
- Phases
Publisher report covers around 35+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Spinal cord injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intracerebral
- Intramedullary injection
- Intra-arterial
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Stem cell therapy
- Growth factor
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Spinal cord injury: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal cord injury therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal cord injury drugs.
Spinal cord injury Report Insights
- Spinal cord injury Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Spinal cord injury Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Spinal cord injury drugs-
- How many Spinal cord injury drugs are developed by each company-
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinal cord injury-
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spinal cord injury therapeutics-
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies-
- What are the clinical studies going on for Spinal cord injury and their status-
- What are the key designations that have been granted to the emerging drugs-
Key Players
- Pfizer
- Eusol Biotech
- Acorda
- Pharmicell
- StemCyte
- Pharmazz
- Neurofix
- Mitsubishi
- AbbVie
- BioAxone
- Novartis
- Syntax
- K-STEMCELL
- Histocell
- Lineage Cell
- ReNetX Bio
- Nordic Life Sciences
- Neuralstem
- Mapreg
- Amkor
- AlaMab
- Kancera
- Neurofix Pharma
- Scholar Rock
- SanBio Co, Ltd.
- Neurimmune
- Novoron Biosciences
- BioAxone BioSciences
Key Products
- KP-100IT
- ES135
- Fampridine
- Cellgram-spine
- MC001
- PMZ-1620
- NFX88
- MT-3921
- Elezanumab
- BA-210
- ATI 355
- XCEL-UMC-BETA
- Astrostem
- FAB 117-HC
- AST-OPC1
- AXER-204
- Spinalon
- NSI-566
- MAP4343
- NEU-2000
- CX 1739
- KAND 567
- NFX-81
- Apitegromab
- SB623
- NG004
- NOVO-118
- NVG-291
Table of Contents
Introduction
Executive Summary
Spinal cord injury: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Spinal cord injury - Publisher Analytical Perspective
In-depth Commercial Assessment
- Spinal cord injury companies' collaborations, Licensing, Acquisition -Deal Value Trends
Spinal cord injury Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
KP-100IT: Kringle Pharma
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
- Comparative Analysis
Elezanumab: Abbvie
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
- Comparative Analysis
NEU-2000: AmKor Pharma
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
- Comparative Analysis
KAND 567: Kancera
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Inactive Products
- Comparative Analysis
Spinal cord injury Key Companies
Spinal cord injury Key Products
Spinal cord injury- Unmet Needs
Spinal cord injury- Market Drivers and Barriers
Spinal cord injury- Future Perspectives and Conclusion
Spinal cord injury Analyst Views
Spinal cord injury Key Companies
Appendix
List of Tables
Table 1 Total Products for Spinal cord injury
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Spinal cord injury
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
- Pfizer
- Eusol Biotech
- Acorda
- Pharmicell
- StemCyte
- Pharmazz
- Neurofix
- Mitsubishi
- AbbVie
- BioAxone
- Novartis
- Syntax
- K-STEMCELL
- Histocell
- Lineage Cell
- ReNetX Bio
- Nordic Life Sciences
- Neuralstem
- Mapreg
- Amkor
- AlaMab
- Kancera
- Neurofix Pharma
- Scholar Rock
- SanBio Co, Ltd.
- Neurimmune
- Novoron Biosciences
- BioAxone BioSciences